MX2021004365A - Conjugados de polinucleotido inmunomoduladores y metodos de uso. - Google Patents

Conjugados de polinucleotido inmunomoduladores y metodos de uso.

Info

Publication number
MX2021004365A
MX2021004365A MX2021004365A MX2021004365A MX2021004365A MX 2021004365 A MX2021004365 A MX 2021004365A MX 2021004365 A MX2021004365 A MX 2021004365A MX 2021004365 A MX2021004365 A MX 2021004365A MX 2021004365 A MX2021004365 A MX 2021004365A
Authority
MX
Mexico
Prior art keywords
methods
immunomodulating polynucleotide
cell
modulating
natural killer
Prior art date
Application number
MX2021004365A
Other languages
English (en)
Spanish (es)
Inventor
Jaume Pons
Bang Janet Sim
Tracy Chia- Chien Kuo
Curt W Bradshaw
Hong I Wan
Original Assignee
Tallac Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tallac Therapeutics Inc filed Critical Tallac Therapeutics Inc
Publication of MX2021004365A publication Critical patent/MX2021004365A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2021004365A 2018-10-17 2019-10-16 Conjugados de polinucleotido inmunomoduladores y metodos de uso. MX2021004365A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862747070P 2018-10-17 2018-10-17
US201862747611P 2018-10-18 2018-10-18
PCT/US2019/056619 WO2020081744A1 (en) 2018-10-17 2019-10-16 Immunomodulating polynucleotide conjugates and methods of use

Publications (1)

Publication Number Publication Date
MX2021004365A true MX2021004365A (es) 2021-07-06

Family

ID=70284225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004365A MX2021004365A (es) 2018-10-17 2019-10-16 Conjugados de polinucleotido inmunomoduladores y metodos de uso.

Country Status (12)

Country Link
US (1) US20220096649A1 (cg-RX-API-DMAC10.html)
EP (1) EP3866858A4 (cg-RX-API-DMAC10.html)
JP (1) JP7536025B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210102204A (cg-RX-API-DMAC10.html)
CN (1) CN113660955A (cg-RX-API-DMAC10.html)
AU (1) AU2019360216A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021007294A2 (cg-RX-API-DMAC10.html)
CA (1) CA3116880A1 (cg-RX-API-DMAC10.html)
IL (1) IL282282B2 (cg-RX-API-DMAC10.html)
MX (1) MX2021004365A (cg-RX-API-DMAC10.html)
SG (1) SG11202103805SA (cg-RX-API-DMAC10.html)
WO (1) WO2020081744A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
MX2024002187A (es) * 2021-08-20 2024-03-12 Tallac Therapeutics Inc Anticuerpos y conjugados de nectina-4.
TW202328185A (zh) * 2021-08-25 2023-07-16 美商泰勒克療法公司 SIRP-α抗體及結合物
WO2023081934A1 (en) * 2021-11-08 2023-05-11 The University Of Chicago Methods and compositions for pkc-delta inhibition and cancer immunotherapy
KR20250039518A (ko) * 2022-05-18 2025-03-20 탈락 테라퓨틱스, 인크. 항-cd22 항체 올리고뉴클레오타이드 접합체를 사용하여 암을 치료하는 방법
AU2025211114A1 (en) * 2024-01-24 2026-06-18 F. Hoffmann-La Roche Ag Linkers for site-specific protein conjugation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061981A (zh) * 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体
CN107109405A (zh) * 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
US20180134802A1 (en) * 2016-01-08 2018-05-17 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
JP2019513692A (ja) * 2016-02-19 2019-05-30 ジェニスフィア・エルエルシー 核酸キャリア及び治療上の使用方法
JOP20190009A1 (ar) * 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها

Also Published As

Publication number Publication date
JP7536025B2 (ja) 2024-08-19
IL282282B1 (en) 2025-03-01
BR112021007294A2 (pt) 2021-07-27
IL282282A (en) 2021-05-31
JP2022508825A (ja) 2022-01-19
EP3866858A4 (en) 2022-10-26
US20220096649A1 (en) 2022-03-31
CN113660955A (zh) 2021-11-16
SG11202103805SA (en) 2021-05-28
IL282282B2 (en) 2025-07-01
AU2019360216A1 (en) 2021-05-13
CA3116880A1 (en) 2020-04-23
WO2020081744A1 (en) 2020-04-23
KR20210102204A (ko) 2021-08-19
EP3866858A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
PH12022551379A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
PH12021550442A1 (en) Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
ZA202310790B (en) Antibody-drug conjugate targeting nectin-4 and preparation method therefor and use thereof
WO2020236825A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
WO2020126620A3 (en) Improved antibody-oligonucleotide conjugate
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12019502288A1 (en) Ask1 inhibitor compounds and uses thereof
EA202191131A1 (ru) Конъюгаты антитело-лекарственное средство, содержащие производные эктеинасцидина
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
PH12019501896A1 (en) Therapeutic dendrimers
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2024010601A (es) Conjugado anticuerpo-farmaco, composicion farmaceutica del mismo y uso del mismo.
EA201891509A1 (ru) Способы лечения рака
MX2023003448A (es) Composicion farmaceutica que comprende conjugado de anticuerpo-farmaco y uso de la misma.
MX2022001678A (es) Derivados amidas hibridas de anfotericina b.
JOP20210045A1 (ar) مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها
SG11202011243XA (en) Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
MX2023005371A (es) Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso.
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
MX2022004341A (es) Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.